Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renewed Confidence In Data, Launches Drive J.P. Morgan Stocks

This article was originally published in The Pink Sheet Daily

Executive Summary

Several big and mid-cap biopharmas successfully maneuvered at the seminal conference for the industry, garnering sizeable stock moves as a reward. But it’s not clear yet if the market upswing signals continued sector momentum or a brief peak.

You may also be interested in...



The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III

TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.

Launching Linzess Into A Tough Primary Care Market

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel